EXACT SCIENCES CORP 4

EVP & CFO Aaron Bloomer received 89,911 shares and concurrently had all 138,679 directly held shares, 417 401(k) shares, and 32,458 RSU-linked shares in Exact Sciences Corp. cancelled/converted for merger consideration in Abbott’s acquisition.

On March 23, 2026, in connection with the closing of Abbott Laboratories’ acquisition of Exact Sciences Corp., EVP and Chief Financial Officer Aaron Bloomer received 89,911 shares of Exact Sciences common stock (likely the settlement of previously granted equity awards) and simultaneously had all of his existing Exact Sciences common stock and equity-based holdings cancelled or converted pursuant to the merger consideration of $105.00 per share. Following the effective time of the merger, his 138,679 directly held shares and 417 shares held indirectly in a 401(k) plan, as well as 4,395 and 28,063 shares underlying restricted stock units, were all disposed of or converted into the contractual right to receive cash or assumed Abbott equity, leaving him with no remaining ownership of Exact Sciences common stock. The transactions are mechanical results of the merger and reflect a full cash-out of his equity in Exact Sciences at the agreed merger price rather than discretionary open-market trading.

Filing Facts

CIK

1124140

Ticker

EXAS

Form

4

Source Type

sec

Accession

0001193125-26-118759

Alert Tier

6